Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-004313-39
    Sponsor's Protocol Code Number:TCH-306EXT
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2023-01-16
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2021-004313-39
    A.3Full title of the trial
    A Multicenter, Open-Label, Extension Trial to Investigate Long Term
    Efficacy and Safety of Lonapegsomatropin in Adults with Growth
    Hormone Deficiency
    foresiGHt: Ensayo multicéntrico, aleatorizado, de grupos paralelos, controlado con placebo (doble ciego) y con tratamiento activo (abierto) para comparar la eficacia y seguridad de lonapegsomatropina una vez a la semana frente a placebo una vez a la semana y un producto de somatropina diaria en adultos con deficiencia de hormona del crecimiento
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    An extension study to check the safety of once weekly lonapegsomatropin when given for a long time in adults with growth hormone deficiency.
    Estudio de extensión para comprobar la seguridad de la administración de lonapegsomatropina a largo plazo en adultos con deficiencia de hormona del crecimiento
    A.4.1Sponsor's protocol code numberTCH-306EXT
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAscendis Pharma Endocrinology Division A/S
    B.1.3.4CountryDenmark
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAscendis Pharma Endocrinology Division A/S
    B.4.2CountryDenmark
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAscendis Pharma A/S
    B.5.2Functional name of contact pointClinical Trial Information Desk
    B.5.3 Address:
    B.5.3.1Street AddressTuborg Boulevard 12
    B.5.3.2Town/ cityHellerup
    B.5.3.3Post codeDK-2900
    B.5.3.4CountryDenmark
    B.5.4Telephone number004570222244
    B.5.6E-mailclinhelpdesk@ascendispharma.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/19/2213
    D.3 Description of the IMP
    D.3.1Product namelonapegsomatropin drug product
    D.3.2Product code ACP-011
    D.3.4Pharmaceutical form Powder and solvent for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNLonapegsomatropin
    D.3.9.1CAS number 1934255-39-6
    D.3.9.2Current sponsor codeACP-011
    D.3.9.3Other descriptive nameTRANSCON PEG40 HGH
    D.3.9.4EV Substance CodeSUB197278
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number12.1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/19/2213
    D.3 Description of the IMP
    D.3.1Product namelonapegsomatropin drug product
    D.3.2Product code ACP-011
    D.3.4Pharmaceutical form Powder and solvent for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNLonapegsomatropin
    D.3.9.1CAS number 1934255-39-6
    D.3.9.2Current sponsor codeACP-011
    D.3.9.3Other descriptive nameTRANSCON PEG40 HGH
    D.3.9.4EV Substance CodeSUB197278
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number24.2
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Adult Growth Hormone Deficiency (AGHD)
    Deficiencia de Hormona del Crecimiento en Adultos (DHCA)
    E.1.1.1Medical condition in easily understood language
    Lack of growth hormone in the body
    Falta de la hormona del crecimeinto en el cuerpo
    E.1.1.2Therapeutic area Diseases [C] - Hormonal diseases [C19]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10056438
    E.1.2Term Growth hormone deficiency
    E.1.2System Organ Class 10014698 - Endocrine disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the safety of once-weekly lonapegsomatropin in adults with GHD previously treated in trial TCH-306.
    Evaluar la seguridad de la lonapegsomatropina administrada una vez por semana en adultos con GHD tratados previamente en el ensayo TCH-306.
    E.2.2Secondary objectives of the trial
    1. To evaluate the efficacy of once-weekly lonapegsomatropin in adults with GHD.
    2. To evaluate the pharmacodynamics (PD) of once-weekly lonapegsomatropin in adults with GHD.
    3. To evaluate the pharmacokinetics (PK) of once-weekly lonapegsomatropin in adults with GHD.
    1. Evaluar la eficacia de la lonapegsomatropina administrada una vez por semana en adultos con GHD.
    2. Evaluar la farmacodinámica (FD) de lonapegsomatropina administrada una vez por semana en adultos con GHD.
    3. Evaluar la farmacocinética (FC) de lonapegsomatropina una vez por semana en adultos con GHD.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Signing of the trial specific informed consent.
    2. Completion of the treatment period and Visit 7 assessments of trial TCH-306, including
    collection and upload of Visit 7 DXA scan.
    3. Fundoscopy at Visit 7 in trial TCH-306 without signs/symptoms of intracranial hypertension
    or diabetic retinopathy stage 2 / moderate or above.
    1. Firma del consentimiento informado específico del ensayo.
    2. Finalización del período de tratamiento y evaluaciones de la visita 7 del ensayo TCH-306, incluyendo la recopilación y subida del escaneo DXA de la Visita 7.
    3. Fundoscopia en la Visita 7 en el ensayo TCH-306 sin signos/síntomas de hipertensión intracraneal o retinopatía diabética estadio 2 / moderado o superior.
    E.4Principal exclusion criteria
    1. Diabetes mellitus if any of the following are met:
    a. Poorly controlled diabetes, defined as HbA1C higher than 7.5% according to central
    laboratory at Visit 6 in trial TCH-306
    b. Use of diabetes mellitus drugs other than metformin and/or dipeptidyl peptidase-4 (DPP-
    4) inhibitors
    2. Active malignant disease or history of malignancy. Exceptions are:
    a. Resection of in situ carcinoma of the cervix uteri
    b. Complete eradication of squamous cell or basal cell carcinoma of the skin
    3. Known history of hypersensitivity and/or idiosyncrasy to the investigational product
    (somatropin or excipients)
    4. Female who is pregnant, plans to become pregnant, or is breastfeeding
    5. Female participant of childbearing potential (i.e., fertile, following menarche and until
    becoming post-menopausal unless permanently sterile) not willing throughout the trial to use
    contraceptives as required by local law or practice. Details included in Appendix 4/section
    10.4 of this protocol
    6. Male participant not willing throughout the trial to use contraceptives as required by local
    law or practice. Details included in Appendix 4/ section 10.4 of this protocol
    7. Any disease or condition that, in the judgement of the investigator, may make the participant
    unlikely to comply with the requirements of the protocol or any condition that presents undue
    risk from the investigational product or trial procedures
    8. eGFR <60 mL/min/1.73m² determined based on Modification of Diet in Renal Disease (MDRD) equation using serum creatinine from the central laboratory at screening
    9. Hepatic transaminases (ie, AST or ALT) >3 times the upper limit of normal according to the central laboratory at screening
    1. Diabetes mellitus si se cumple alguno de los siguientes:
    a. Diabetes mal controlada, definida como HbA1C superior al 7,5% según el laboratorio central en la visita 6 en el ensayo TCH-306.
    b. Uso de cualquier medicamento para la diabetes mellitus distinto de metformina y/o inhibidores de dipeptidil peptidasa-4 (DPP-4).
    2. Enfermedad maligna activa o antecedentes de neoplasia maligna. Las excepciones son:
    a. Resección de carcinoma cervicouterino in situ
    b. Erradicación completa del carcinoma de células escamosas o de células basales de la piel
    3. Antecedentes conocidos de hipersensibilidad y/o idiosincrasia al producto en investigación (somatropina o excipientes)
    4. Mujer que está embarazada, planea quedar embarazada o se encuentra en período de lactancia.
    5. Participante femenina en edad fértil (es decir, fértil, después la menarquia y hasta
    volverse posmenopáusica, a menos que esté permanentemente estéril) que no esté dispuesta a usar métodos anticonceptivos durante todo el ensayo según lo requieran las leyes o prácticas locales. Detalles incluidos en el Apéndice 4/sección 10.4 de este protocolo
    6. El participante masculino no esté dispuesto a usar métodos anticonceptivos durante todo el ensayo según lo requiera la legislación o prácticas locales. Detalles incluidos en el Apéndice 4/sección 10.4 de este protocolo
    7. Cualquier enfermedad o afección que, a juicio del investigador, pueda hacer que sea poco probable que el sujeto cumpla con los requisitos del protocolo o cualquier afección que presente un riesgo del producto en investigación o de los procedimientos del ensayo.
    8. TFGe <60 ml/min/1,73 m² determinada según la ecuación de modificación de la dieta en la enfermedad renal (MDRD) utilizando la creatinina sérica del laboratorio central en la selección.
    9. Transaminasas hepáticas (es decir, AST o ALT) > 3 veces el límite superior de la normalidad según el laboratorio central en la selección
    E.5 End points
    E.5.1Primary end point(s)
    • Adverse events (AEs)
    • Laboratory values
    • Vital signs
    • Immunogenicity
    • 12-lead electrocardiogram (ECGs)
    • Fundoscopy
    • Eventos adversos (EA)
    • Valores analíticos
    • Constantes vitales
    • Inmunogenicidad
    • Electrocardiograma (ECG) de 12 derivaciones
    • Fundoscopia
    E.5.1.1Timepoint(s) of evaluation of this end point
    throughout the treatment period of 52 weeks
    durante todo el período de tratamiento de 52 semanas
    E.5.2Secondary end point(s)
    Efficacy endpoints (as assessed by dual-X-rayabsorptiometry
    (DXA):
    • Trunk percent fat
    • Trunk fat mass
    • Total body lean mass

    PD endpoints:
    • IGF-1 values and IGF-1 SDS

    PK endpoints:
    • hGH, lonapegsomatropin, and mPEG values
    Criterios de valoración de la eficacia (evaluados mediante absorciometría de rayos X de energía dual (DXA)):
    • Porcentaje de grasa del tronco
    • Masa grasa del tronco
    • Masa magra corporal total

    Citerios de valoración FD:
    • Niveless de IGF-1 y SDS de IGF-1

    Criterios de valoración FC:
    • Niveles de hGH, lonapegsomatropina y mPEG
    E.5.2.1Timepoint(s) of evaluation of this end point
    Efficacy endpoints At week 52
    PD endpoints throughout the treatment period of 52 weeks
    PK endpoints from week 17 to week 52
    Criterios de valoración de la eficacia en la semana 52
    Criterios de valoración de la FD a lo largo del período de tratamiento de 52 semanas
    Criterios de valoración de FC desde la semana 17 hasta la semana 52
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA48
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Canada
    Israel
    Japan
    New Zealand
    United States
    France
    Poland
    Bulgaria
    Netherlands
    Romania
    Spain
    Germany
    Greece
    Italy
    Armenia
    Belarus
    Denmark
    Georgia
    Russian Federation
    Slovakia
    Turkey
    Ukraine
    United Kingdom
    Serbia
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    UVUS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months11
    E.8.9.1In the Member State concerned days1
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months2
    E.8.9.2In all countries concerned by the trial days6
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 195
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 45
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state50
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 80
    F.4.2.2In the whole clinical trial 240
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Access to the trial drug after trial end will not be offered to any of the participants. Effective
    drugs for the indication are commercially available.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2023-04-10
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2023-03-16
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 04 00:08:24 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA